ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.62
0.96%
US Tech 100
18,129.20
0.56%
S&P 500
5,277.51
0.80%
US Dollar vs CAD
1.36632
0.08%
Bitcoin
69,053.37
1.93%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Merck and Co Inc (MRK)

  7. Merck and Co Inc (MRK) News

MRK

Merck (MRK)

Merck and Co Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:MRK
DateTimeSourceHeadlineSymbolCompany
05/30/20243:39PMEdgar (US Regulatory)Form CERT - Certification by an exchange approving securities for listingNYSE:MRKMerck and Co Inc
05/30/20243:28PMEdgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NYSE:MRKMerck and Co Inc
05/30/20243:14PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:MRKMerck and Co Inc
05/29/20248:10AMIH Market NewsRising Treasury Yields May Weigh On Wall StreetNYSE:MRKMerck and Co Inc
05/29/20246:34AMIH Market NewsRobinhood Shares Surge 3.3% on Stock Buyback Announcement; Anglo Declines BHP Deadline Extension, and More NewsNYSE:MRKMerck and Co Inc
05/29/20246:15AMBusiness WireFDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural MesotheliomaNYSE:MRKMerck and Co Inc
05/29/20245:45AMBusiness WireMerck to Acquire EyeBioNYSE:MRKMerck and Co Inc
05/28/20243:44PMIH Market NewsNasdaq Climbs To Another Record Closing High But Dow Sees Further DownsideNYSE:MRKMerck and Co Inc
05/28/20243:31PMEdgar (US Regulatory)Form SD - Specialized disclosure reportNYSE:MRKMerck and Co Inc
05/28/20242:12PMBusiness WireMerck Announces Third-Quarter 2024 DividendNYSE:MRKMerck and Co Inc
05/28/20245:45AMBusiness WireMerck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)NYSE:MRKMerck and Co Inc
05/20/20245:28AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:MRKMerck and Co Inc
05/16/20243:15PMEdgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNYSE:MRKMerck and Co Inc
05/15/202410:31AMEdgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNYSE:MRKMerck and Co Inc
05/15/20245:45AMBusiness WireMerck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse PipelineNYSE:MRKMerck and Co Inc
05/13/20245:45AMBusiness WireMerck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk MelanomaNYSE:MRKMerck and Co Inc
05/09/20246:05AMPR Newswire (Canada)Santé Canada approuve KEYTRUDA® pour le traitement, en association avec une chimiothérapie à base de gemcitabine, des adultes atteints d'un carcinome des voies biliaires non résécable localement avancé ou métastatiqueNYSE:MRKMerck and Co Inc
05/09/20246:05AMPR Newswire (Canada)Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapyNYSE:MRKMerck and Co Inc
05/09/20245:45AMBusiness WireMerck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative IntentNYSE:MRKMerck and Co Inc
05/08/20245:45AMBusiness WireMerck to Participate in the Bank of America Securities 2024 Healthcare ConferenceNYSE:MRKMerck and Co Inc
05/06/20243:29PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:MRKMerck and Co Inc
05/06/20243:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
05/06/20243:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
05/06/20243:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
05/06/20243:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
05/01/20246:15AMBusiness WireMerck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaNYSE:MRKMerck and Co Inc
04/29/20248:00AMBusiness WireMerck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for AdultsNYSE:MRKMerck and Co Inc
04/25/20243:40PMIH Market NewsU.S. Stocks Climb Well Off Worst Levels But Close Mostly LowerNYSE:MRKMerck and Co Inc
04/25/20248:09AMIH Market NewsFutures Pointing To Sharply Lower Open On Wall StreetNYSE:MRKMerck and Co Inc
04/25/20246:52AMIH Market NewsSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on EarningsNYSE:MRKMerck and Co Inc
 Showing the most relevant articles for your search:NYSE:MRK

Your Recent History

NYSE
GME
GameStop
USOTC
IFUS
Impact Fusion (PK)
USOTC
AXXA
Exxe (PK)
NASDAQ
DJT
Trump Media and Technology
USOTC
PHIL
PHI (PK)
NASDAQ
COOP
Mr Cooper
USOTC
VPLM
Voip Pal Com (QB)
USOTC
BMXI
Brookmount Explorations (PK)
USOTC
PSRU
Valiant Eagle (PK)
NYSE
AMC
AMC Entertainment
NASDAQ
LWLG
Lightwave Logic
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
NASDAQ
AVXL
Anavex Life Sciences
NASDAQ
AMRN
Amarin
USOTC
RDGL
Vivos (QB)
USOTC
NSAV
Net Savings Link (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved